Current Research Studies
The Crohn’s & Colitis Foundation of America supports several major ongoing research initiatives and clinical studies to encourage cooperative efforts among investigators, research centers, and other resources.
Explore the initiatives below to learn more about the broad range of IBD research studies supported by CCFA and how you can become more involved in this important work.
CCFA partnered with the Center for Genome Sciences at Washington University to develop greater understanding of the role of gut microbes (bacteria, viruses, etc. that are found normally in the intestines) in digestive health and inflammatory bowel diseases. Using the latest generation of massively parallel DNA sequencers and sophisticated computational methods, the initiative studies the complex role that intestinal microbial communities play in digestive health and disease.
The Genetics Initiative continues the work of several recent studies that have demonstrated how specific organisms in the gut can cause inflammatory bowel diseases in the presence of specific genes, and that specific genes only cause disease in the presence of specific organisms. The Genetics Initiative is a collaborative effort to better understand the genes and their functions, and the chain of biological events that result in IBD (the pathogenesis of inflammatory bowel diseases).
Pediatric Risk Stratification Initiative
The Pediatric RiskStratification Initiative is working to “crack the code” of disease prognosis by identifying measurable risk factors for the complications of severe disease. CCFA’s Professional KIIDS Pediatric Network is committed to identifying the genetic, microbiological, and immunological factors that are predictive of more severe disease. The resulting knowledge will translate into new protocols for individualized approaches to treating inflammatory bowel diseases in children and the prevention of severe disease and itslifelong consequences.
CCFA Partners is a comprehensive Internet-based registry designed to study thousands of patients with Crohn's disease or ulcerative colitis under a single research initiative.Unlike prior research, which has typically been conducted in small studies at major medical centers, CCFA Partners tracks the individual experience of more than 10,000 patients diagnosed with inflammatory bowel diseasesthrough three- and six-month reporting updates conducted online.
CCFA Clinical Research Alliance
The Clinical Research Alliance is a network of major medical centers and smaller, local facilities collaborating on clinical studies of the management and treatment of IBD. Members include hospitals, medical centers, clinics, and research facilities that have developed an IBD-related research program administered by a principal investigator.
CCFA DNA Bank
The CCFA DNA Bank contains DNA samples and detailed phenotype data on a large number of Crohn's disease and ulcerative colitis patients. The DNA Bank enhances research into genetic markers and determinants that affect risk for these inflammatory bowel diseases. Coordinating these data assists researchers seeking to understand the underlying disease process in order to improve disease treatment and prevention.
Ocean State Crohn’s & Colitis Area Registry
The Ocean State Crohn’s & Colitis Area Registry (OSCCAR) is a collaborative effort of Massachusetts General Hospital and Rhode Island Hospital. In Rhode Island, a small yet diverse population provides an excellent opportunity for demographic-based studies of inflammatory bowel diseases.
Autoimmune Diseases in Pregnancy Study
The Autoimmune Diseases in Pregnancy Study is being conducted by the Organization of Teratology Information Specialists (OTIS) and is coordinated by the University of California, San Diegoto learn about effects Crohn's disease and other autoimmune diseases have on the outcome of pregnancies.
Pregnancy in Inflammatory Bowel Disease and Neonatal Outcomes: A National Prospective Registry
The PIANO study (Pregnancy in Inflammatory Bowel Disease and Neonatal Outcomes) was initiated in August 2007 and has enrolled over four hundred patients across the United States. The objective of the registry is to determine whether there is a higher rate of adverse events in a prospective national sample of women from the US with IBD who are being treated with azathioprine/6MP or anti-TNF biologic drugs (infliximab, adalimumab, certolizumab). Thirty member sites of the CCFA Clinical Alliance identified and followed a prospective cohort of pregnant women with IBD. Data were collected each trimester of pregnancy at delivery and every four months in the first year of the child's life.
Voices of Progress
This colloquium brought together leading researchers to share their latest work in therapies, genetics, nutrition, and much more.